# Biologics for eosinophilic COPD: current applications and future prospects

## TL;DR

This review discusses new biologics for COPD patients with eosinophilic inflammation and highlights the importance of biomarkers for better treatment.

## Contribution

The paper reviews emerging biologics targeting type 2 inflammation in COPD and emphasizes the role of biomarkers.

## Key findings

- Eosinophilic COPD patients remain at risk of exacerbations despite standard therapy.
- Monoclonal antibodies targeting type 2 pathways show promise in treating eosinophilic COPD.
- Accurate biomarkers are essential for identifying patients who may benefit from these biologics.

## Abstract

Chronic obstructive pulmonary disease (COPD) is a heterogeneous pulmonary disorder characterized by persistent airflow limitation and symptoms of progressive dyspnea, cough, and sputum. While traditionally linked to type 1 immunity, a significant subset of patients presents with eosinophil-predominant type 2 inflammation. These individuals remain at risk of exacerbations despite receiving triple therapy, underscoring the need for novel biologics targeting type 2 pathways. Monoclonal antibodies against targets such as IL-5/IL-5Rα, IL-4, IL-13, IL-33/ST-2, and thymic stromal lymphopoietin (TSLP) have shown considerable promise. Therefore, the identification of accurate and accessible biomarkers for type 2 inflammation is crucial. This review summarizes the current applications and future prospects of emerging biologics in eosinophilic COPD, with a specific focus on the role of biomarkers.